- NSE
Beta Drugs
Healthcare NSE:BETA
1387.20INR
117.10
(
9.22%)
Last update at April 2, 2026, midnight
Day Range
52 Week Range
Fundamentals
- Previous Close 1270.10
- Market Cap 16575.26M
- Volume21,966
- P/E Ratio 25.70
- EBITDA 756.73M
- Revenue TTM 3856.46M
- Revenue Per Share TTM 493.66
- Gross Profit TTM 1530.21M
- Diluted EPS TTM 63.90
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Past Performance
| Status | Stocks | Entry Price | Entry Date | Exit Date | Duration | Duration Type | Sector | *Return(%) |
|---|---|---|---|---|---|---|---|---|
| CLOSED | CIPLA | ₹ 1515.70 | 4/11/25 | 4/11/25 | Same Day | Short Term | Healthcare | -0.79% |
| CLOSED | CIPLA | ₹ 1499.85 | 18/03/25 | 18/03/25 | Same Day | Short Term | Healthcare | 0.72% |
| CLOSED | CIPLA | ₹ 1452.00 | 11/03/25 | 11/03/25 | Same Day | Short Term | Healthcare | 0.69% |
| CLOSED | CIPLA | ₹ 1457.00 | 14/02/25 | 14/02/25 | Same Day | Short Term | Healthcare | 0.24% |
Financials
No income statement data available.
No balance sheet data available.
No cash flow data available.
Peer Comparison
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change | Price | Market Cap (M) | P/E Ratio |
|---|---|---|---|---|
| BETA Beta Drugs |
117.10 9.22% | 1387.20 | 16575.26 | 25.70 |
| SUNPHARMA Sun Pharmaceutical Industries Limited |
-34.90 -2.02% | 1693.60 | 4224508.76 | 40.32 |
| DIVISLAB Divi's Laboratories Limited |
-50.00 -0.85% | 5856.50 | 1752225.28 | 70.47 |
| TORNTPHARM Torrent Pharmaceuticals Limited |
-124.10 -3.02% | 3987.20 | 1362716.66 | 63.48 |
| CIPLA Cipla Limited |
-3.50 -0.29% | 1192.40 | 1183505.97 | 21.74 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data ("EODHD") on an 'as is' basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.